Patents by Inventor Lars Abrahmsen
Lars Abrahmsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139352Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: March 8, 2023Publication date: May 2, 2024Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Patent number: 11633507Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: GrantFiled: December 10, 2020Date of Patent: April 25, 2023Assignees: GENERAL ELECTRIC COMPANY, AFFIBODY ABInventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Publication number: 20220339141Abstract: Provided herein are methods of treating hyperproliferative malignancy in a subject using combination of a compound that can result in reactivation of mutant p53 and a Bcl-2 inhibitor or a Mcl-1 inhibitor. Also provided herein are methods of treating lymphoma in a subject using a combination therapy of a p53 reactivator, a Bcl 2 inhibitor, and rituximab.Type: ApplicationFiled: September 18, 2020Publication date: October 27, 2022Inventors: Lars Abrahmsén, Anders Wennborg
-
Publication number: 20210170057Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: December 10, 2020Publication date: June 10, 2021Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Patent number: 10894097Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: GrantFiled: September 27, 2018Date of Patent: January 19, 2021Assignees: GENERAL ELECTRIC COMPANY, AFFIBODY ABInventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Publication number: 20200199197Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29 (SEQ ID NO:1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: January 15, 2020Publication date: June 25, 2020Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Patent number: 10562955Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: December 14, 2017Date of Patent: February 18, 2020Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Patent number: 10556933Abstract: Populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ (SEQ ID NO: 1) or AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q (SEQ ID NO: 2), wherein each X individually corresponds to an amino acid residue which is varied in the population are disclosed. Also populations of polynucleotides, wherein each member encodes a member of a polypeptide population are disclosed. Furthermore, combinations of such polypeptide populations and such polynucleotide populations are disclosed, wherein each member of polypeptide population is physically or spatially associated with the polynucleotide encoding that member via means for genotype-phenotype coupling.Type: GrantFiled: August 16, 2016Date of Patent: February 11, 2020Assignee: AFFIBODY ABInventors: Lars Abrahmsén, Nina Herne, Christofer Lendel, Joachim Feldwisch
-
Publication number: 20190375799Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.Type: ApplicationFiled: May 8, 2019Publication date: December 12, 2019Inventors: Caroline Ekblad, Lars Abrahmsen
-
Publication number: 20190284241Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: April 8, 2019Publication date: September 19, 2019Inventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Publication number: 20190262481Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: September 27, 2018Publication date: August 29, 2019Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Patent number: 10329331Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.Type: GrantFiled: December 1, 2015Date of Patent: June 25, 2019Assignee: AFFIBODY ABInventors: Caroline Ekblad, Lars Abrahmsen
-
Patent number: 10323066Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: September 17, 2015Date of Patent: June 18, 2019Assignee: AFFIBODY ABInventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Patent number: 10159760Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: GrantFiled: March 29, 2016Date of Patent: December 25, 2018Assignee: General Electric CompanyInventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Patent number: 10118949Abstract: The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans.Type: GrantFiled: November 24, 2014Date of Patent: November 6, 2018Assignee: AFFIBODY ABInventors: Lars Abrahmsén, Andreas Jonsson, Jakob Dogan, Per-Åke Nygren
-
Publication number: 20180230235Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN LX16X17X18QX20X21AFIX25X26LWD (SEQ ID NO. 369). The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.Type: ApplicationFiled: March 28, 2018Publication date: August 16, 2018Inventors: Lars Abrahmsén, Ingmarie Höidén-Guthenberg, Elin Gunneriusson
-
Patent number: 9975943Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: March 17, 2014Date of Patent: May 22, 2018Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20180118807Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: December 14, 2017Publication date: May 3, 2018Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Patent number: 9957330Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN?LX16X17X18QX20?X21AFIX25X26LWD. The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.Type: GrantFiled: December 19, 2013Date of Patent: May 1, 2018Assignee: AFFIBODY ABInventors: Lars Abrahmsén, Ingmarie Höidén-Guthenberg, Elin Gunneriusson
-
Patent number: 9873729Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: March 17, 2014Date of Patent: January 23, 2018Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löblom, Torbjörn Gräslund, Johan Seijsing